Oncopeptides AB (FRA:OND) Interest Coverage: N/A (As of Mar. 2026)

Oncopeptides AB  (FRA:OND) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

Oncopeptides AB Interest Coverage Related Terms

The historical data trend for Oncopeptides AB's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Oncopeptides AB Interest Coverage Chart

Oncopeptides AB Annual Data
	Trend	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24	Dec25
Interest Coverage		Get a 7-Day Free Trial					0.00	0.00	0.00	0.00	0.00

Oncopeptides AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Coverage	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	N/A

FRA:OND vs VRTX, REGN, ALNY: Interest Coverage Comparison

For the Biotechnology subindustry, Oncopeptides AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's Interest Coverage falls into.

Oncopeptides AB Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Else if Interest Expense is negative and Operating Income is negative, then

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oncopeptides AB's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Oncopeptides AB's Interest Expense was €-1.33 Mil. Its Operating Income was €-20.76 Mil. And its Long-Term Debt & Capital Lease Obligation was €12.10 Mil.

Oncopeptides AB's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Oncopeptides AB's Interest Expense was €0.00 Mil. Its Operating Income was €-3.48 Mil. And its Long-Term Debt & Capital Lease Obligation was €12.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Oncopeptides AB Business Description